Live price temporarily unavailable.
Ultragenyx Pharmaceutical (RARE) is a Health Care company in the Russell 2000. Latest news and coverage below.
Ultragenyx Pharmaceutical revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $133.0K | $2.61M | $51.5M | $103.7M | $271.0M | $351.4M | $363.3M | $434.0M | $560.0M | $673.0M |
| Growth (year over year) | — | +1863.9% | +1871.5% | +101.4% | +161.3% | +29.7% | +3.4% | +19.5% | +29.0% | +20.2% |
| Gross profit | — | $2.61M | $50.3M | — | — | — | — | — | — | — |
| Gross margin | — | 100.0% | 97.8% | — | — | — | — | — | — | — |
| Operating income | −$248.0M | −$328.9M | −$371.4M | −$424.2M | −$330.1M | −$381.7M | −$648.9M | −$569.0M | −$536.0M | −$535.0M |
| Operating margin | −186471.4% | −12593.5% | −721.2% | −409.0% | −121.8% | −108.6% | −178.6% | −131.1% | −95.7% | −79.5% |
| Net income | −$245.9M | −$302.1M | −$197.6M | −$402.7M | −$186.6M | −$454.0M | −$707.4M | −$607.0M | −$569.0M | −$575.0M |
| Net margin | −184867.7% | −11567.3% | −383.7% | −388.3% | −68.8% | −129.2% | −194.7% | −139.9% | −101.6% | −85.4% |
| EPS (diluted) | −$6.21 | −$7.12 | −$3.97 | −$7.12 | −$3.07 | −$6.70 | −$10.12 | −$8.25 | −$6.29 | −$5.83 |
| Balance sheet | ||||||||||
| Cash and equivalents | $161.1M | $100.5M | $113.4M | $433.6M | $713.5M | $307.6M | $132.9M | $214.0M | $174.0M | $421.0M |
| Total assets | $540.6M | $490.8M | $719.6M | $1.14B | $1.76B | $1.52B | $1.55B | $1.49B | $1.50B | $1.53B |
| Total liabilities | $66.7M | $107.3M | $110.7M | $481.7M | $605.2M | $599.8M | $1.19B | $1.22B | $1.24B | $1.60B |
| Shareholders' equity | $474.0M | $383.5M | $608.9M | $653.8M | $1.15B | $922.6M | $352.0M | $275.0M | $255.0M | −$80.0M |
| Cash flow | ||||||||||
| Operating cash flow | −$161.0M | −$253.8M | −$290.6M | −$345.4M | −$132.2M | −$338.7M | −$380.5M | −$475.0M | −$414.0M | −$466.0M |
| Capital expenditure | $10.2M | $2.79M | $4.08M | $24.8M | $43.9M | $73.1M | $116.1M | $44.0M | $7.00M | $6.00M |
| Free cash flow | −$171.2M | −$256.6M | −$294.6M | −$370.2M | −$176.1M | −$411.8M | −$496.6M | −$519.0M | −$421.0M | −$472.0M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $139.5M | $164.6M | $139.0M | $167.0M | $159.9M | $207.1M | $136.0M | $214.0M |
| Growth (year over year) | +42.3% | +29.5% | +27.7% | +13.6% | +14.7% | +25.8% | −2.2% | +28.1% |
| Operating income | −$132.0M | −$122.3M | −$143.0M | −$108.0M | −$170.9M | −$113.1M | −$169.0M | −$75.0M |
| Operating margin | −94.6% | −74.3% | −102.9% | −64.7% | −106.9% | −54.6% | −124.3% | −35.0% |
| Net income | −$133.5M | −$133.2M | −$151.0M | −$115.0M | −$180.4M | −$128.6M | −$185.0M | −$92.0M |
| Net margin | −95.7% | −80.9% | −108.6% | −68.9% | −112.8% | −62.1% | −136.0% | −43.0% |
| EPS (diluted) | −$1.40 | −$1.34 | −$1.57 | −$1.17 | −$1.81 | −$1.28 | −$1.84 | −$0.90 |
| Balance sheet | ||||||||
| Cash and equivalents | $150.6M | $174.0M | $127.0M | $176.0M | $202.5M | $421.0M | $175.0M | $125.0M |
| Total assets | $1.54B | $1.50B | $1.31B | $1.31B | $1.19B | $1.53B | $1.30B | $1.26B |
| Total liabilities | $1.18B | $1.24B | $1.16B | $1.15B | $1.17B | $1.60B | $1.52B | $1.55B |
| Shareholders' equity | $346.8M | $255.0M | $144.0M | $151.0M | $9.16M | −$80.0M | −$236.0M | −$291.0M |
| Cash flow | ||||||||
| Operating cash flow | −$67.0M | −$79.3M | −$166.0M | −$109.0M | −$91.2M | −$99.8M | −$197.0M | −$97.0M |
| Capital expenditure | $1.62M | $163.0K | $1.00M | $3.00M | $1.06M | $938.0K | $1.00M | $1.00M |
| Free cash flow | −$68.6M | −$79.5M | −$167.0M | −$112.0M | −$92.2M | −$100.8M | −$198.0M | −$98.0M |
From Ultragenyx Pharmaceutical's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Source: Wikipedia — Ultragenyx
- Headquarters
- Novato, California From SEC filings, Oct 2026
Recent News (1)
Other Health Care companies to compare with RARE
- QSI Quantum Si Inc Class a
- QTRX Quanterix Corp
- RANI Rani Therapeutics Holdings
- RAPP Rapport Therapeutics Inc
- RCEL Avita Medical Inc
- RCKT Rocket Pharmaceuticals Inc
- RCUS Arcus Biosciences Inc
- RDNT Radnet Inc